Amgen (Nasdaq: AMGN) announced new data from three separate analyses of Phase 2 and 3 studies evaluating evolocumab, a novel ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE